Commentary: Data monitoring confidentiality and FDA transparency

London AJ Kimmelman J Carlisle B . Rethinking research ethics: the case of postmarketing trials. Science 2012; 336: 544–545.

Food and Drug Administration (FDA). Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf

Fleming TR . Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 2015; 12: 5–11.

Grant AM Altman DG Babiker AB .; DAMOCLES Study Group. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005; 9: 25.

National Research Council. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press, 2007.

Nissen SE Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.

Ledford H . FDA debates trial-data secrecy. Nature 2014; 511: 519.

Lilford RJ Braunholtz D Edwards S . Monitoring clinical trials—interim data should be publicly available. BMJ 2001; 323: 441–442.

Stephens RJ Langley RE Mulvenna P . Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential? Lung Cancer 2014; 85: 116–118.

Eichler HG Oye K Baird LG . Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91: 426–437.